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Aim of the study: To determine whether
the expression of HER-3 influences the
survival of HER-2 positive patients with
breast cancer (BC).
Material and methods: In the present
work, the expression of HER-3 in a group
of 35 HER-2 positive patients with BC
was studied by performing immuno-
histochemistry (IHC) in formalin-fixed
paraffin embedded tissues.
Results: Higher HER-3 status if estimated
by IHC correlated significantly with old-
er age of the patients. HER-3 expression
did not correlate with estrogen or prog-
esterone receptor status, pT or pN.
There was also no significant difference
in disease-free or overall survival (DFS
and OS) between groups with different
HER-3 expression, although some ten-
dencies were seen as HER-3 expression
in over 50% of cells was a factor of worse
5- and 10-year survival.
Conclusions: Further studies should be
performed on a larger group of patients
to confirm the prognostic role of HER-3
status determined by IHC in BC.
Key words: breast cancer, HER-2, HER-3,
immunohistochemistry, prognostic fac-
tor.
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Introduction
Despite the decline in breast cancer (BC) mortality in Europe, this neoplasm
remains the main cause of death worldwide among women with cancer and
its incidence is increasing. In the last 20 years several prognostic factors have
been identified in BC. Among these, were steroid receptors (SR), such as estro-
gen (ER) and progesterone (PR) receptors, as well as human epidermal growth
factor receptor-2 (HER-2), which have a special significance. In fact, we are cur-
rently moving from a purely morphological to a molecular cancer classifica-
tion, and SR-positive, HER-2 positive and double-negative cancers constitute
a surrogate of molecular grouping [1–3]. HER-2 positive BCs are regarded as
aggressive, poorly differentiated tumors. However, they can usually be effec-
tively treated with a targeted antibody, e.g. trastuzumab. HER-2 is a member
of the epithelial growth factor receptor (EGFR) family, consisting of HER-1, 
HER-2, HER-3 and HER-4. If specific ligands are present, the EGFR family members 
dimerize, cross phosphorylize, and pass downstream signals through their intrin-
sic kinase activity. EGFRs are present on the surface of normal epithelial, mes-
enchymal and neural cells, and have been shown to be overexpressed on a num-
ber of neoplastic cells [4]. In several cancer types significant (10× up to 100×)
overexpression of HERs may be observed. This leads to increased mitogenic
signaling [5]. While overexpression of HER-2 activates one of the main mito-
genic pathways, HER-3 stimulates the most important antiapoptotic pathway
[6]. HER-2 overexpression or amplification is documented in 15% to 30% of
invasive BC, while the rate for HER-3 is not well defined. Different papers report
prevalence of 10% to 75% in all patients with BC [7–11]. The negative prog-
nostic value of HER-2 is well known. Relatively little attention has been paid
to the prognostic significance of HER-1, HER-3 or HER-4. There are some papers
suggesting increased mortality in HER-3 positive BC [7, 8, 12–14].
Currently, little is known about the significance of HER-2 and HER-3 co-expres-
sion; however, it has been proved that this co-expression is common. HER-3
creates heterodimers with other HER family members including HER-2.
Blocking HER-2 or HER-3 decreases the activity of the other receptor [7, 15,
16]. HER-2/HER-3 heterodimers stimulate cancer growth through the phos-
phatidylinositol-3-kinase (PI3-K)/protein kinase B (AKT) pathway [7].
The aim of the present study was to investigate the prognostic significance
of HER-3 expression in HER-2 positive breast cancer patients.
Material and methods
The study group consisted of 69 patients with BC treated radically at the Oncol-
ogy Department of Jagiellonian University (UJ) between 1994 and 2004, and show-
ing HER-2 3+ overexpression in immunohistochemistry (IHC). The patients were
selected according to the availability of the material and its quality. The stain-
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ings were performed on paraffin-embedded tissues from 35
patients. Tissue blocks were derived from the files of the Depart-
ment of Pathomorphology UJ. The material was fixed in for-
malin, routinely processed, and embedded in paraffin. For each
case, a single representative block was selected, and used 
for the IHC. From the selected blocks, 4 µm thick sections 
were cut, and placed on SuperFrost+ (SuperFrost Inc.) coat-
ed slides. Endogenous peroxidase was blocked for 10 minutes
in a 3% H2O2 solution. Antigen retrieval was performed in EDTA
buffer (pH 8.0; 0.01 M) that was heated to 98°C for 30 min-
utes in a water bath. The slides were incubated with a primary
antibody (DAKO Corp., clone DAK-H3-IC) diluted 1 : 100 for 
30 minutes. The Lab Vision (Thermo Fisher Scientific Corp.)
detection system with 3-amino-9-ethylcarbazole (DAKO Corp.)
as chromogen was used for visualization. Mayer hema-
toxylin counterstaining was used.
Microscopic slides were assessed using a Nikon Eclipse
80i microscope. In every case, the cancer cells showing expres-
sion HER-3 in the cytoplasm and cellular membranes were
counted, and the staining intensity was classified semi-quan-
titatively (“++” – strong reaction, “+” – weak reaction, “0” –
no reaction).
Through this process, expression of HER-3 was estimat-
ed as the percentage of HER-3 positive cells and HER-3 stain-
ing intensity [8].
The observation of the patients was conducted until June
2010. The data about clinical staging, ER, PR, local recurrence,
and distant metastases were collected.
The research protocol was approved by the Jagiellonian
University Ethics Committee (registry KBET/165/B/2010). The
study was performed in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki and its
later amendments.
Baseline patients’ characteristics were compared between
the two groups by Mann-Whitney U test or Fisher’s exact test
as appropriate. The Kaplan-Meier (KM) method was used to
calculate the distribution of disease-free survival (DFS) and
overall survival (OS). Results of KM analysis are presented
as 5- and 10-year DFS and OS estimates with 95% confidence
intervals (CI). The impact of quantitatively measured HER-3
(i.e. percentage of positive cells) on DFS and OS was
assessed by hazard ratios (HR), with 95% confidence inter-
vals, resulting from the Cox proportional hazard regression
model. A p-value < 0.05 was considered significant. Statis-
tical analysis was performed with R 2.13 software.
Results
Exemplary HER-3 stainings in HER-2 positive BC tissue sam-
ples are presented in Fig. 1A–C.
The basic characteristics of patients in relation to HER-3
status is shown in Table 1. Median age of all 35 patients was
54.4 (interquartile range 48.4–63.5, range 31–86). In the cur-
rent study the frequency of combined overexpression of both
HER-2 and HER-3 was 45.7%. Patients with both HER-2 and
HER-3 overexpression were significantly older than patients
with HER-3 negative status. There were no differences in terms
of tumor size or lymph nodes involved between the two
groups. Also, no statistically significant correlation was found
for ER or PR.
In Table 2, survival in relation to HER-2 and HER-3 status
is shown. The 5- or 10-year OS was not dependent on HER-3
receptor status; however, 10-year survival suggests a weak-
er discriminative power of HER-3 qualitative assessment.
A stronger suggestion, although, again, not statistically sig-
nificant, arises from the analysis of DFS (Table 3). For OS HR
for every 25% increase in HER-3 positive cells assessment
is established as 1.233 (95% CI: 0.621–2.446), and for DFS as
1.064 (95% CI: 0.711–1.593).
Discussion
Theoretically, combined HER-2 and HER-3 expression
should worsen the prognosis in comparison to HER-2
Fig. 1. HER-3 staining in HER-2 positive breast cancer tissue samples
HER-3 staining intensity classified semi-quantitatively as: (0) – no reaction, (+) – weak reaction, (++) – strong reaction (objective 60×).
A) (0) Lack of HER-3 reaction, B) (+) cytoplasmic reaction present, C) (++) cytoplasmic and cellular membrane reaction present
A B C
Table 1. Characteristics of patients treated for breast cancer
between 1994 and 2004 in relation to HER-2 and HER-3 status
Feature HER-2 positive HER-2 and HER-3 p value
and HER-3 positive status** 
negative status* (N = 16)
(N = 19)
Age (years)*** 48.9 (44.9–56.7) 61.3 (52.7–70.3) 0.008
pT1 14 (73.7%) 11 (68.7%) > 0.05
pT2-4 5 (26.3%) 5 (31.2%) > 0.05
pN0 10 (52.7%) 8 (50.0%) > 0.05
pN1-3 9 (56.3%) 8 (50%) > 0.05
ER (+) 9 (47%) 12 (75%) > 0.05
PR (+) 12 (67%) 13 (81%) > 0.05
*HER-3 percentage of positive cells 0–50%
**HER-3 percentage of positive cells > 50%
***Median (1st–3rd quartile)
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expression alone. Such a phenomenon, although not sta-
tistically significant, may be observed in our analysis, espe-
cially when disease-free survival is considered. Lack of sta-
tistical significance may be due to the small sample size, and
requires further confirmation in larger studies.
It may be assumed that combined overexpression of both
HER-2 and HER-3 will require development of new therapeutic
modalities with monoclonal antibodies directed against both
of these receptors.
The second interesting point in our results is the differ-
ence of quantitative versus qualitative HER-3 receptor as -
sessment. HER-3 expression in over 50% of cells was a neg-
ative prognostic factor in 5- and 10-year survival. However,
the group of patients with increased staining intensity showed
some improvement in survival. This anomalous result
should be regarded as false positive, probably due to the small
sample size.
In fact, it has already been shown by other authors that
the HER-3 assessment method influences results in terms
of survival analysis [8].
In the literature, a correlation between HER-3 expression
and lymph node status has been suggested [17]. In our study
such a link was not observed. HER-3 expression has also been
correlated with positive ER and PR status [18]. Regarding the
obtained results, some tendency in terms of ER, although not
statistically significant, could be seen.
There are data suggesting positive [19], and negative 
HER-3 prognostic value [9, 20]. In a study with more than 200
breast cancer tissues, overexpression of HER-3 reduced
patients’ survival [17]. This correlation was also seen in some
studies at the RNA level, although the clinical parameters are
usually correlated with the expression of HER family mem-
bers at the protein level [7, 17]. There is also one recent paper
where the negative prognostic HER-3 status value was con-
firmed on more than 4000 tumor samples [8]. Because of
the differences between the separate studies, the compar-
ison of the data may be difficult.
The staining pattern of HER-3 is not entirely clear accord-
ing to the literature. Some investigators have reported pre-
dominant cytoplasmic HER-3 staining in esophageal [21] and
ovarian [22] cancer, whereas cytoplasmic and membranous
expression pattern have been reported in colorectal [23], gas-
tric [24] and BC [9]. There is also a report of HER-3 staining
restricted to the cytoplasm in laryngeal carcinoma [25].
The discrepancies may be partially explained by the dif-
ference of antibodies used for staining or method of assess-
ment of HER-3 status. However, there are no standardized
methods of HER-3 staining and scoring, and according to the
manufacturer of the antibody we used (Dako Corp.), both
staining patterns (cytoplasmic and membranous) may be
equally regarded as positive [26].
In conclusion, the co-overexpression of HER-2 and HER-3
may lead to worse BC patients’ survival. However, the sam-
ple size in the current study was probably too small. Thus,
it should be confirmed in a larger population. Also, the stan-
dardization of the assessment method is essential. Further
research is necessary to answer additional questions, e.g. if
the expression of HER-3 may change in the course of the dis-
ease, as this type of switch is observed for HER-2 [27]. The
studies concerning possible prognostic and predictive fac-
tors in BC bring us closer to understanding the mechanisms
of oncogenesis, and enhance the possibility of more adequate
patients' treatment [28].
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